Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899318 | 1.00 | TSHR (0.44) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL15754827 | 0.83 | TSHR (0.40) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL29210964 | 0.81 | TSHR (0.38) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL453090 | 0.80 | TSHR (0.42) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL7821073 | 0.80 | TSHR (0.42) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL9187017 | 0.80 | TSHR (0.42) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL28564049 | 0.79 | THRB (0.46) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL32685382 | 0.79 | THRB (0.46) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL8830567 | 0.79 | THRB (0.46) | TSHRTP53EGLN1EGLN3LMNA | |
| SCHEMBL16178793 | 0.79 | THRB (0.46) | TSHRTP53EGLN1EGLN3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562834-B2 | Process for preparing substituted crotonic acids | INTERVET INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562834-B2 | Process for preparing substituted crotonic acids | INTERVET INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2831042-B1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | INTERVET INT BV (NL) | 2019-07-31 | — | — | EP | disclosed |
| US-20190135725-A1 | PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135725-A1 | PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20170121265-A1 | IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121265-A1 | IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-3145904-A1 | IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | Intervet International B.V. (NL) | 2017-03-29 | — | — | EP | disclosed |
| EP-2621923-B1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INT BV (NL) | 2017-03-29 | — | — | EP | disclosed |
| EP-2621903-B1 | N-HETEROARYL COMPOUNDS | INTERVET INT BV (NL) | 2017-03-01 | — | — | EP | disclosed |
| US-9321724-B2 | Heteroaryl compounds with A-cyclic bridging unit | INTERVET INC. (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2015177179-A1 | IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INTERNATIONAL B.V. (NL) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015177179-A1 | IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INTERNATIONAL B.V. (NL) | 2015-11-26 | — | — | WO | disclosed |
| US-20150057279-A1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| US-8883791-B2 | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases | INTERVET INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8877934-B2 | N-heteroaryl compounds | INTERVET INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INC. | 2013-08-08 | — | — | US | disclosed |
| EP-2621903-A1 | N-HETEROARYL COMPOUNDS | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | INTERVET INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2012041873-A1 | N-HETEROARYL COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135725-A1 | PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | CROCC, CMA1, HSD11B1 | TSHR 518/4885TP53 4420/4885EGLN1 1086/4885 |
| US-10562834-B2 | Process for preparing substituted crotonic acids | CROCC, CMA1, HSD11B1 | TSHR 518/4885TP53 4420/4885EGLN1 1086/4885 |
| US-20150057279-A1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | AADAC, PIGS, MTCL3 | TSHR 4575/4885TP53 4835/4885EGLN1 888/4885 |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | HNMT, SQLE, PIGO | TSHR 4440/4885TP53 4822/4885EGLN1 696/4885 |
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | PIGO, HNMT, PIGS | TSHR 4181/4885TP53 4840/4885EGLN1 772/4885 |
| US-20170121265-A1 | IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | CROCC, CMA1, HSD11B1 | TSHR 661/4885TP53 4561/4885EGLN1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.